AVTX's free cash flow for Q4 2023 was $-2.80M. For the 2023 fiscal year, AVTX's free cash flow was decreased by $-3.99M and operating cash flow was $―. See a summary of the company’s cash flow.

Cash Flow	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Operating Cash Flow	$ -17.63M	$ -30.70M	$ -26.75M	$ -70.89M	$ -40.54M	$ -19.13M
Investing Cash Flow	$ -133.00K	$ -133.00K	$ -95.00K	$ -113.00K	$ 11.13M	$ -443.00K
Financing Cash Flow	$ 25.04M	$ 25.04M	$ -14.70M	$ 106.76M	$ 44.78M	$ 12.56M
Cash Flow From Discontinued Operation	-	-	-	-	-	-
Other Cash Adjustment Inside Changein Cash	-	-	-	-	-	-
End Cash Position	$ 16.91M	$ 7.55M	$ 13.32M	$ 54.86M	$ 19.11M	$ 3.73M
Income Tax Paid Supplemental Data	-	-	-	-	$ 474.00K	$ 1.80M
Interest Paid Supplemental Data	$ 1.93M	$ 1.93M	$ 2.93M	$ 1.58M	$ 0.00	$ 1.05M
Issuance Of Capital Stock	$ 67.00K	$ 67.00K	$ 73.00K	$ 29.41M	$ 44.45M	$ 12.68M
Issuance Of Debt	$ -21.24M	$ -21.24M	$ -14.81M	-	$ 0.00	-
Repayment Of Debt	$ -21.24M	$ -21.24M	$ -14.81M	-	$ 0.00	$ -256.14K
Free Cash Flow	$ -20.43M	$ -30.83M	$ -26.85M	$ -71.00M	$ -40.60M	$ -19.40M
Domestic Sales	-	-	-	-	-	-
Foreign Sales	-	-	-	-	-	-

Currency in USD

Avalo Therapeutics Cash Flow

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing